Head-to-head · WeighScore
Direct Meds vs NewSelf
The verdict
NewSelf takes it — 85/100 to 82/100.
NewSelf grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide, $144 tirzepatide, verified and available in all 50 states.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Direct Meds | NewSelf |
|---|---|---|
| WeighScore | 82/100 | 85/100 |
| Grade | B− | B |
| Scorecard rank | #27 | #11 |
| Semaglutide | $179/mo | $100/mo |
| Tirzepatide | $224/mo | $144/mo |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #27 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Graded #11 · B
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.